Role of progenitor cells in transplant arteriosclerosis

Jan-Luuk Hillebrands1, Geanina Onuta, Jan Rozing

  • 1Department of Cell Biology, Section Immunology & Histology, University Medical Center Groningen, A. Deusinglaan 1, NL-9713 AV Groningen, The Netherlands. j.l.hillebrands@med.rug.nl

Insights

Chronic transplant dysfunction (CTD) causes long-term transplant loss by obliterating arteries. Host-derived vascular progenitor cells, not just graft cells, are key drivers of this transplant arteriosclerosis (TA).

Area of Science:

  • Transplantation immunology
  • Vascular biology
  • Regenerative medicine

Background:

  • Chronic transplant dysfunction (CTD) is the primary cause of long-term graft loss.
  • A hallmark of CTD is transplant arteriosclerosis (TA), characterized by occlusive neointima formation in graft arteries.
  • The precise etiology of TA remains largely unknown, hindering effective prevention and treatment.

Purpose of the Study:

  • To investigate the cellular origins of neointimal lesions in transplant arteriosclerosis.
  • To challenge the traditional "response-to-injury" hypothesis by exploring the role of host-derived cells.
  • To identify potential therapeutic targets for preventing TA.

Main Methods:

  • Histologic analysis of intragraft arterial lesions.
  • Cellular source tracing of neointimal cells (vascular smooth muscle cells and endothelial cells).
  • Investigation of circulating vascular progenitor cells.

Main Results:

  • Neointimal lesions in TA consist of vascular smooth muscle cells, extracellular matrix, inflammatory cells, and endothelial cells.
  • Recent findings suggest a significant role for host-derived vascular progenitor cells in TA development.
  • These progenitor cells may originate from the bone marrow and contribute to neointima formation.

Conclusions:

  • The development of TA is a heterogeneous process involving multiple cell sources.
  • Host-derived circulating vascular progenitor cells are implicated in TA pathogenesis.
  • Targeting these progenitor cells offers a promising therapeutic strategy to prevent transplant arteriosclerosis and improve long-term graft survival.

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Tissue Transplantation01:24

Tissue Transplantation

Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...